NCT07070466 2026-03-06
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
Phase 2 Recruiting
Clinical Trials
94 trialsNCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05802056 2025-12-19
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
Phase 1 Recruiting
NCT07283939 2025-12-16
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Alliance for Clinical Trials in Oncology
Phase NA Not yet recruiting
NCT03161522 2025-10-23
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07085273 2025-07-31
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT03421288 2025-07-25
DANTE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT02366819 2025-06-13
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Recruiting
NCT06028737 2025-05-06
OCTASUR
Ukrainian Society of Clinical Oncology
Phase 2/3 Recruiting
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT01286766 2024-12-27
Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma
Yonsei University
Phase 2 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04745988 2024-11-15
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT04447352 2024-11-12
PREVENT
Krankenhaus Nordwest
Phase 3 Recruiting
NCT04937738 2024-11-06
PECORINO
Ukrainian Society of Clinical Oncology
Phase 2 Terminated
NCT04547153 2024-03-25
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Completed
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT03283761 2024-02-06
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT05264896 2023-09-07
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Phase 3 Recruiting
NCT02333188 2023-05-31
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
University of Chicago
Phase 1 Completed
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01212822 2022-09-07
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT02661971 2022-07-11
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Completed
NCT04997837 2021-08-10
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Fudan University
Phase 3 Recruiting
NCT04358354 2021-07-19
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT04393584 2021-04-13
RusGCG-01
Blokhin's Russian Cancer Research Center
Phase 2/3 Unknown
NCT04442984 2021-04-13
IRIGA
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00002883 2021-02-23
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
UNICANCER
Phase 3 Completed
NCT04354662 2021-02-18
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT01183559 2021-01-22
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
Phase 1 Completed
NCT04595929 2020-11-25
GASPACCO
St. Petersburg State Pavlov Medical University
Phase NA Recruiting
NCT02114359 2020-10-23
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
Seoul National University Hospital
Phase 3 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT04358341 2020-08-24
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT01913639 2020-05-15
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01643499 2020-05-08
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
Phase 1 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04269369 2020-02-13
Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients
Jessa Hospital
Phase 4 Unknown
NCT00525785 2020-02-10
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00515411 2019-12-10
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03023436 2019-09-13
Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT01216644 2019-06-19
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Phase 2/3 Completed